The Fair Pricing Coalition (FPC) supports the U.S. Food and Drug Administration’s (FDA) approval of Harvoni, Gilead Sciences’ new treatment for the hepatitis C virus (HCV), according to an FPC statement. However, the HIV and hep C advocacy group wants the drug company to establish a price for Harvoni treatment that isn’t based on how many weeks people take the once-daily pill.

Combining Sovaldi (sofosbuvir) and ledipasvir, Harvoni does not require either interferon or ribavirin. In its statement, the FPC concurs with Gilead that Harvoni has long-term cost-saving potential. The FPC also acknowledges that Gilead has continued to maintain a free medications program for low-income, uninsured HCV-positive patients.

However, the FPC wants Gilead to extend the eight-week wholesale acquisition cost (WAC) for Harvoni to all patients, regardless of their duration on the drug. The current WAC for Harvoni is set at $1,125 per pill, which translates to $63,000 for eight weeks of treatment, $94,500 for 12 weeks and $189,000 for 24 weeks.

The FPC argues that setting a flat price of $63,000 would help ensure patients needing longer treatments would not be restricted because of cost from taking Harvoni, which the FDA approved October 10.